HYPERTRIGLYCERIDEMIA THERAPEUTICS MARKET ANALYSIS (2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
HYPERTRIGLYCERIDEMIA THERAPEUTICS MARKET ANALYSIS
(2020-2027)

• Hypertriglyceridemia Therapeutics Market, by Type
  (Primary and Secondary), by Drug Class (Statins,
  Fibrates, Niacin, Omega-3 Fatty Acids, and
  HMG-CoA Reductase inhibitors), by Distribution
  Channel (Online Pharmacy, Retail Pharmacy,
  Hospital Pharmacy, and Others), and by Region
  (North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa) - Size, Share,
  Outlook, and Opportunity Analysis, 2020 - 2027

3

• Hypertriglyceridemia is a common disorder or
  condition in which the triglyceride levels in the
  blood are elevated. The increasing levels of
  triglyceride are mainly related to
  atherosclerosis and cardiovascular diseases
  (CVDs). This condition also causes
  pancreatitis, atherosclerosis, and other CVDs.
  New advancements in terms of diagnosis and
  treatment of hypertriglyceridemia for rapidly
  recovering the triglyceride levels in the human
  body are expected to boost the global
  hypertriglyceridemia therapeutics market growth.
• The key players are investing in research
  development and commercialization of novel drugs
  for the treatment of hypertriglyceridemia, which
  is expected to boost the market growth during the
  forecast period. Moreover, the growing prevalence
  of cardiovascular diseases and increasing
  sedentary habits are other factors propelling the
  market growth. For instance, according to the
  World Health Organization (WHO), around 17.9
  million deaths reported in 2016 were due to
  cardiovascular diseases which are the leading
  cause of death across the globe.

4
Global Hypertriglyceridemia Therapeutics Market -
Impact of Coronavirus (Covid-19) Pandemic

• The hypertriglyceridemia therapeutics market
  growth has been impacted significantly due to the
  outbreak of COVID-19 across the world. As per the
  EMCrit Project, COVID-19 affected patients are
  more prone to developing hypertriglyceridemia,
  mainly due to systemic inflammation. Thus,
  ideally keeping the propofol dosages can help to
  maintain sedation and prevent conditions such as
  hypertriglyceridemia. It is becoming difficult
  for researchers and key industry players to
  perform clinical trials during this pandemic
  crisis. However, many market players such as Eli
  Lilly and Company, and Pfizer Inc. are investing
  in research and development of novel
  hypertriglyceridemia drugs.

5

• The all-inclusive version of the report will
  include the impact of COVID-19 and the probable
  changes in the future outlook of the industry, by
  taking into account the technological, social,
  political, and economical parameters.
• The hypertriglyceridemia therapeutics market is
  estimated to be valued at US 9,716.6 million in
  2020 and is expected to register a CAGR of
  4.09 during the forecast period (2020-2027).

6
Figure 1. Global Hypertriglyceridemia
Therapeutics Market Share () Analysis, By Type,
2020
7

• The increasing research development of drugs
  are expected to propel the global
  hypertriglyc eridemia therapeutics market growth
  during the forecast period
• Key players are investing to in development of
  novel drugs and launching these products in the
  market which in turn, is estimated to
  significantly boost the market growth and create
  lucrative growth opportunities in the global
  hypertriglyceridemia therapeutics market during
  the forecast period.

8

• For instance, in July 2019, Sun Pharma launched
  Ezallor Sprinkle (Rosuvastatin) in the U.S. for
  the people having difficulty swallowing. Ezallor
  Sprinkle capsules are indicated as an adjunct to
  the diet for the hypertriglyceridemia adult
  patients treatment. It is also indicated as an
  adjunct to diet for the treatment of adult
  patients with type III hyperlipoproteinemi and to
  other lipid-lowering treatments.
• Furthermore, the increasing number of drug
  approvals are expected to help companies
  strengthen their market position. For instance,
  in December 2019, Amarin received FDA approval
  for VASCEPA (icosapent ethyl) indicated for
  reducing cardiovascular risk. The novel
  indication for VASCEPA is that it is an adjunct
  to diet to reduce triglyceride levels in older
  patients with severe hypertriglyceridemia.

9
(No Transcript)
10
Hypertriglyceridemia Therapeutics Market
Regional Analysis

• North America accounted for majority of the share
  in the global hypertriglyceridemia therapeutics
  market in 2019 and is expected to retain its
  dominance during the forecast period. This is
  majorly attributed to the growing healthcare
  expenditure, FDA approvals, and product launches
  in the hypertriglyceridemia therapeutics market.
  For instance, in July 2016, Mylan launched
  Rosuvastatin Calcium Tablets in the U.S., which
  are the generic version of Crestor (AstraZenecas
  tablet). The company received the U.S. Food and
  Drug Administration (FDA) approval for their ANDA
  (Abbreviated New Drug Application). Crestor
  tablets are used in combination with diet for
  treating hypertriglyceridemia in adults.

11

• Moreover, the growing prevalence of obesity in
  the U.S. is projected to boost the growth of the
  regional market during the forecast period. For
  instance, according to the Centers for Disease
  Control and Prevention (CDC), the prevalence of
  obesity in the U.S. was 42.4 in 2017 and the
  rate is increasing at a rapid pace.
• Furthermore, the market in Asia Pacific is
  expected to witness significant growth during the
  forecast period owing to drug approvals and surge
  in prevalence of cardiovascular diseases in the
  region. As per the Department of Nutrition and
  Health Sciences, cardiac problems account for
  seven out of every 10 deaths in Asian countries.

12

• Figure 2. Global Hypertriglyceridemia
  Therapeutics Market Value (US Mn) Y-o-Y Growth
  (), 2017-2027

13
Global Hypertriglyceridemia Therapeutics Market -
Competitive Landscape

• Key players operating in the global
  hypertriglyceridemia therapeutics market are
  Sanofi, GlaxoSmithKline Plc, Biocon, Novo Nordisk
  A/S, Tonghua Dongbao Pharmaceutical Co., Ltd.,
  Oramed Pharmaceuticals, Inc, Merck Co., Inc.,
  Julphar, Eli Lilly and Company, Bristol-Myers
  Squibb Company, Pfizer Inc., Adocia, Hikma
  Pharmaceutical plc, Lupin Ltd., AbbVie Inc.,
  Wockhardt Ltd., Zydus Pharmaceuticals, Glenmark
  Pharmaceuticals, Amneal pharmaceutical LLC,
  Aurobindo Pharma, and Accord Healthcare.

14

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/
  market-insight/hypertriglyceridemia-therapeutics-m
  arket-4020

15
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

16
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

17

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/